Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 5 February 2025
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 26 March 2025
Alzheimer's disease (early) - gantenerumab [ID6142]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC